The GPR75 Knockout A-549 Polyclonal Cells comprise a heterogeneous population of A-549 human lung adenocarcinoma epithelial cells that have undergone CRISPR/Cas9-mediated disruption of the GPR75 gene. This knockout model, provided as a polyclonal population, enables loss-of-function studies of the orphan G protein-coupled receptor GPR75 within a physiologically relevant cancer cell context. The polyclonal format reflects a broad spectrum of editing events, making it suitable for pooled functional screens and bulk biochemical analyses. Gene disruption effectively abolishes GPR75 protein expression, allowing researchers to interrogate its role in signaling and metabolism.
The A-549 cell line, originally derived from the tumor tissue of a 58-year-old Caucasian male with lung adenocarcinoma, serves as a well-established model of alveolar type II pulmonary epithelium. These cells retain characteristics of human lung adenocarcinoma and are extensively used in cancer biology and metabolic research. The parental A-549 line exhibits robust in vitro growth and is amenable to genetic manipulation, making it an ideal host for CRISPR-mediated knockout studies.
GPR75 is an orphan class A GPCR implicated in metabolic regulation and energy homeostasis. Upon activation by an unknown endogenous ligand, GPR75 primarily couples to heterotrimeric G proteins of the Gs and Gi families, leading to modulation of adenylate cyclase (ADCY) activity and consequent changes in intracellular cAMP levels. This second messenger cascade propagates signaling through protein kinase A (PRKACA) and downstream effectors including the mitogen-activated protein kinases MAPK1 (ERK2) and MAPK3 (ERK1). Additionally, GPR75 engages ??-arrestin-2, which may mediate G-protein-independent signaling or receptor desensitization. Key transcriptional targets such as CREB link GPR75 to gene expression programs that influence cellular metabolism, proliferation, and survival.
In the context of A-549 lung adenocarcinoma cells, GPR75 knockout provides a powerful tool to dissect the intersection between GPCR signaling and cancer metabolism. Given emerging links between obesity, metabolic syndrome, and cancer progression, this model is particularly relevant for studying how orphan GPCRs contribute to metabolic reprogramming in tumor cells. Disruption of GPR75 may impair glucose uptake, alter MAPK pathway activity, and affect proliferative capacity, offering insights into its potential as a therapeutic target in obesity-driven malignancies.
Researchers can leverage this polyclonal knockout population in a variety of downstream applications. Standard validation assays include Sanger sequencing to confirm gene editing at the population level, western blotting to assess loss of GPR75 protein, and RT-qPCR to measure transcript levels. Functional studies may encompass cell proliferation assays, cAMP measurement using ELISA or biosensors, glucose uptake assays to probe metabolic effects, and migration assays to evaluate metastatic potential. This model is suitable for drug target validation screens, pathway dissection via inhibitor or ligand treatments, and comparative omics analyses. For more details, please contact Ascent Research.
